Menarini Ricerche S.p.a.

A. Menarini S.a.s.

Istituto Luso Farmaco D'italia

A. Menarini Industrie Farmaceutiche Riunite S.r.l.

Laboratori Guidotti

Berlin-chemie Ag

Malesci Istituto Farmacobiologico S.p.a.

Menarini Richerche S.p.a.

A. Menatini Industrie Farmaceutiche

A. Menarini Industrie Farmaceutiche Riunite S.t.l.

Carlo Alberto Maggi

Vittorio Pestellini

Alberto Meli

Danilo Giannotti

Laura Quartara

Mario Ghelardoni

Alessandro Giolitti

Sandro Giuliani

Stefano Manzini

Maria Altamura

Aldo Salimbeni

Patrizia Felicetti

Gabrio Roncucci

Cristina Rossi

Damiano Turozzi

Christopher Ingo Fincham

Federico Maria Arcamone

Alessandro Sisto

Carlo Pedone

Fabio Animati

Valerio Caciagli

Amalia Cipollone

Davide Poma

Vincenzo Pavone

Mario Bigioni

Raffaello Giorgi

Enzo Perrotta

Paolo Rovero

Angelina Lombardi

Valentina Fedi

Cristina Di Bugno

Franco Pasqui

Rossano Nannicini

Nicholas Harmat

Marco Berettoni

Antonio Guidi

Rosa Terracciano

Fernando Catrambone

Federico Calvani

Riccardo Patacchini

Paolo Santicioli

Giovanni Viti

Alberto Aleotti

Guglielmo Grimaldi

Disclosed are pharmaceutical compositions containing, as the active ingredients, a mixture of a hyaluronic acid polymer with a bradykinin B2 receptor antagonist. Said compositions have proved especially effective in the treatment of degenerative joint diseases such as osteoarthritis using intra-articular injections.

Pharmaceutical compositions containing bradykinin antagonists and hyaluronic acid, and uses thereof

Disclosed are pharmaceutical compositions containing, as active ingredients, a mixture of a corticosteroid and a kinin B2 receptor antagonist. Said compositions have proved particularly effective, especially in the treatment of inflammatory disorders such as asthma, ophthalmic or dermatological disorders and, above all, as regards the joints, arthritis.

Pharmaceutical compositions based on kinin B2 receptor antagonists and corticosteroids, and their use

A new process for the preparation of bicyclic peptide compounds Formula (I) in high yields of high purity, useful as intermediates for preparing compounds with pharmacological activity, is described. 

Process for the preparation of bicyclic peptide compounds

Pharmaceutical compositions containing NK2 antagonists are described, useful for the treatment of infantile colics.

Pharmaceutical compositions based on NK2 antagonists for pediatric use

Non-peptide compounds having activity as selective antagonists of bradykinin (BK) B2 receptor are disclosed. The compounds have the general formula (I) in which R is hydrogen or methyl; W is a single bond or an oxygen atom; n=3; X is hydrogen or a &#x2014;NRRamino group in which Rand Rcan be independently hydrogen or a group which is methyl, ethyl, n-propyl, or isopropyl; Y is a &#x2014;NRRRquaternary ammonium group in which RRRcan be independently a group which is methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, or n-pentyl; and the enantiomers and enantiomeric mixtures thereof. Pharmaceutical compositions containing these compounds and methods of using the compounds to treat patients having conditions, disorders or diseases involving activation of bradykinin B2 receptors are also disclosed.

Non-peptide bradykinin antagonists and pharmaceutical compositions therefrom

Non-peptide compounds of formula (I) having activity as specific antagonists of bradykinin (BK) B2 receptor. The compounds are chemically characterized by the presence of an alpha, alpha-disubstituted amino acid at least one amino group, free or salified, or the corresponding ammonium quaternary salt. These BK receptor antagonists are a novel class of medicaments which can be used in all the disorders in which the receptors are involved.

Basic non-peptide bradykinin antagonists and pharmaceutical compositions therefrom

Described herein are compounds of formula (I) useful as antagonists of tachykinins in general, and in particular of neurokinin A; and the pharmaceutical formulations comprising the compounds of formula (I) 

Linear basic compounds having NK-2 antagonist activity and formulations thereof

Basic monocyclic compounds having general formula (I) useful as NK-2 antagonists are described, processes for their preparation and pharmaceutical compositions containing them are also described.

Basic monocyclic compounds having Nk2 antagonist action, processes for their preparation, and formulations containing them

Process of preparing (E)-5-(2-bromovynyl)-2'-deoxyuridine (Brivudine) characterized in that halogen-free solvent selected form esters or cyclic ethers are used in the bromination step of 5-ethyl-2&#x2032;-deoxyuridine diacylate. The use of solvents is advantageous in respect of toxicity, discharge costs and environment protection.

Process for the preparation of (e)-5-(2-bromovinyl)-2'-deoxyuridine

Monocyclic compounds with four bifunctional residues having NK-2 antagonist action

The present invention refers to compounds of general formula (I), the pharmaceutically acceptable salts thereof, the processes for their preparation, and the pharmaceutical compositions containing them.

L-arabino-disaccharides of anthracyclines, processes for their preparation, and pharmaceutical compositions containing them

This invention relates to novel compounds of general formula (I): ##STR1## and to pharmaceutical compositions containing them.

Bicyclic tachykinins antagonists, preparation thereof and their use in

Tachyikinin antagonist compounds of the general formula: ##STR1## are described where: X1, X2, X3, X4, X5, and X6 are identical or different and are --NR'--CO-- or --CO--NR'--, where R' is H or C.sub.1-3 alkyl;

Tachiquinine antagonist tricyclic compounds, preparation of same and

A synthetic peptide corresponding to the following formula:

Synthetic peptide antagonists of neurokinin A, salts thereof and

Use of a 10-amino-5,6-dihydro-11H-dibenzo(b,e)azepine-6,11-dione of formula I ##STR1## where R represents an atom of hydrogen or a lower alkyl group, especially containing from 1 to 5 carbon atoms, as well as of a therapeutically acceptable salt of said compound, to prepare a drug for use in the treatment of urinary incontinence.

Therapy of 10-amino-5,6-dihydro-11H-dibenzo(b,e)azepine-6,11-dione and

Growing community of inventors

Florence, Italy

Carlo Alberto Maggi